The HIV-1/HAART associated metabolic syndrome - Novel adipokines, molecular associations and therapeutic implications

Journal of Infection

Volumn 61, Issue 2, 2010, Pages 101-113

  Tsiodras, S ^a   Perelas, A ^a   Wanke, C ^b   Mantzoros, C S ^c  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Adipocytokines; Adipokines; AIDS; HIV 1; Metabolic syndrome

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; ACYLATION STIMULATING PROTEIN; ADIPONECTIN; ANTIRETROVIRUS AGENT; APELIN; ATAZANAVIR; FORKHEAD TRANSCRIPTION FACTOR; GLITAZONE DERIVATIVE; LEPTIN; MEMBRANE PROTEIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OMENTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PROTEINASE INHIBITOR; RESISTIN; RETINOL BINDING PROTEIN 4; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSIGLITAZONE; UNCLASSIFIED DRUG; VASPIN; ADIPOCYTOKINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

BODY MASS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DNA REPLICATION; DOWN REGULATION; DRUG INDUCED DISEASE; DRUG USE; DYSLIPIDEMIA; GLUCOSE HOMEOSTASIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERTRIGLYCERIDEMIA; HYPOLEPTINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPOATROPHY; LIPODYSTROPHY; LIPOHYPERTROPHY; METABOLIC DISORDER; METABOLIC SYNDROME X; MOLECULAR DYNAMICS; OBESITY; PATHOGENESIS; PROTEIN FUNCTION; REVIEW; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; VIRUS REPLICATION; CHEMICALLY INDUCED; COMPLICATION; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; PHYSIOLOGY;

ADIPOKINES; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS;

EID: 77955055258     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2010.06.002     Document Type: Review

References (200)

1. Hammer S.M., Squires K.E., Hughes M.D., Grimes J.M., Demeter L.M., Currier J.S., et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725-733. AIDS Clinical Trials Group 320 Study Team.
2. Behrens G., Dejam A., Schmidt H., Balks H.J., Brabant G., Korner T., et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999, 13:F63-F70.
3. Carr A., Cooper D.A. Images in clinical medicine. Lipodystrophy associated with an HIV-protease inhibitor. N Engl J Med 1998, 339:1296.
4. Tsiodras S., Mantzoros C., Hammer S., Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med 2000, 160:2050-2056.
5. Vigouroux C., Gharakhanian S., Salhi Y., Nguyen T.H., Chevenne D., Capeau J., et al. Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART). Diabetes Metab 1999, 25:225-232.
6. Engelson E.S., Kotler D.P., Tan Y., Agin D., Wang J., Pierson R.N., et al. Fat distribution in HIV-infected patients reporting truncal enlargement quantified by whole-body magnetic resonance imaging. Am J Clin Nutr 1999, 69:1162-1169.
7. Garg A. Acquired and inherited lipodystrophies. N Engl J Med 2004, 350:1220-1234.
8. Hauner H. The new concept of adipose tissue function. Physiol Behav 2004, 83:653-658.
9. Trayhurn P., Wood I.S. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004, 92:347-355.
10. Jan V., Cervera P., Maachi M., Baudrimont M., Kim M., Vidal H., et al. Altered fat differentiation and adipocytokine expression are inter-related and linked to morphological changes and insulin resistance in HIV-1-infected lipodystrophic patients. Antivir Ther 2004, 9:555-564.
11. Hengel R.L., Watts N.B., Lennox J.L. Benign symmetric lipomatosis associated with protease inhibitors. Lancet 1997, 350:1596.
12. Guaraldi G., Orlando G., Squillace N., Roverato A., De Fazio D., Vandelli M., et al. Prevalence of and risk factors for pubic lipoma development in HIV-infected persons. J Acquir Immune Defic Syndr 2007, 45:72-76. 1999.
13. Rahim S., Ortiz O., Maslow M., Holzman R. A case-control study of gynecomastia in HIV-1-infected patients receiving HAART. AIDS Read 2004, 14:23-24. 9-32, 5-40.
14. Bacchetti P., Gripshover B., Grunfeld C., Heymsfield S., McCreath H., Osmond D., et al. Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr 2005, 40:121-131. 1999.
15. Fat distribution in women with HIV infection. J Acquir Immune Defic Syndr 2006, 42:562-571. 1999.
16. Jacobson D.L., Knox T., Spiegelman D., Skinner S., Gorbach S., Wanke C. Prevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women. Clin Infect Dis 2005, 40:1837-1845.
17. Mallal S.A., John M., Moore C.B., James I.R., McKinnon E.J. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000, 14:1309-1316.
18. Estrada V., Martinez-Larrad M.T., Gonzalez-Sanchez J.L., de Villar N.G., Zabena C., Fernandez C., et al. Lipodystrophy and metabolic syndrome in HIV-infected patients treated with antiretroviral therapy. Metabolism 2006, 55:940-945.
19. Lichtenstein K.A., Delaney K.M., Armon C., Ward D.J., Moorman A.C., Wood K.C., et al. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr 2003, 32:48-56. 1999.
20. McDermott A.Y., Terrin N., Wanke C., Skinner S., Tchetgen E., Shevitz A.H. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study. Clin Infect Dis 2005, 41:1662-1670.
21. Mallon P.W., Miller J., Cooper D.A., Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 2003, 17:971-979.
22. Shevitz A., Wanke C.A., Falutz J., Kotler D.P. Clinical perspectives on HIV-associated lipodystrophy syndrome: an update. AIDS 2001, 15:1917-1930.
23. Martin A., Smith D.E., Carr A., Ringland C., Amin J., Emery S., et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 2004, 18:1029-1036.
24. McComsey G.A., Ward D.J., Hessenthaler S.M., Sension M.G., Shalit P., Lonergan J.T., et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL Study. Clin Infect Dis 2004, 38:263-270.
25. Murphy R, Katlama C, Weverling G-J, Hoff F, Roubenoff R, Berzins B, et al. Fat redistribution and metabolic study (FRAMS) in patients receiving a nucleoside reverse transcriptase inhibitor, or protease inhibitor-based regimen over 4 years: FRAMS II substudy of the Atlantic Study. In: 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, California; 2004 February 8-11.
26. Reiss P., Casula M., de Ronde A., Weverling G.J., Goudsmit J., Lange J.M. Greater and more rapid depletion of mitochondrial DNA in blood of patients treated with dual (zidovudine+didanosine or zidovudine+zalcitabine) vs. single (zidovudine) nucleoside reverse transcriptase inhibitors. HIV Med 2004, 5:11-14.
27. Cherry C.L., Gahan M.E., McArthur J.C., Lewin S.R., Hoy J.F., Wesselingh S.L. Exposure to dideoxynucleosides is reflected in lowered mitochondrial DNA in subcutaneous fat. J Acquir Immune Defic Syndr 2002, 30:271-277. 1999.
28. Shikuma C.M., Hu N., Milne C., Yost F., Waslien C., Shimizu S., et al. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. AIDS 2001, 15:1801-1809.
29. Jones S.P., Qazi N., Morelese J., Lebrecht D., Sutinen J., Yki-Jarvinen H., et al. Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens. J Acquir Immune Defic Syndr 2005, 40:565-572. 1999.
30. Ross S.E., Hemati N., Longo K.A., Bennett C.N., Lucas P.C., Erickson R.L., et al. Inhibition of adipogenesis by Wnt signaling. Science 2000, 289:950-953. (New York, NY).
31. Jemsek J.G., Arathoon E., Arlotti M., Perez C., Sosa N., Pokrovskiy V., et al. Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients. Clin Infect Dis 2006, 42:273-280.
32. Kim R.J., Wilson C.G., Wabitsch M., Lazar M.A., Steppan C.M. HIV protease inhibitor-specific alterations in human adipocyte differentiation and metabolism. Obesity 2006, 14:994-1002. (Silver Spring).
33. Jones S.P., Waitt C., Sutton R., Back D.J., Pirmohamed M. Effect of atazanavir and ritonavir on the differentiation and adipokine secretion of human subcutaneous and omental preadipocytes. AIDS 2008, 22:1293-1298.
34. Bastard J.P., Caron M., Vidal H., Jan V., Auclair M., Vigouroux C., et al. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 2002, 359:1026-1031.
35. Pacenti M., Barzon L., Favaretto F., Fincati K., Romano S., Milan G., et al. Microarray analysis during adipogenesis identifies new genes altered by antiretroviral drugs. AIDS 2006, 20:1691-1705.
36. Adams M., Montague C.T., Prins J.B., Holder J.C., Smith S.A., Sanders L., et al. Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. J Clin Invest 1997, 100:3149-3153.
37. Hadigan C., Miller K., Corcoran C., Anderson E., Basgoz N., Grinspoon S. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 1999, 84:1932-1937.
38. Carr A., Samaras K., Burton S., Law M., Freund J., Chisholm D.J., et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51-F58.
39. Kotler D.P., Rosenbaum K., Wang J., Pierson R.N. Studies of body composition and fat distribution in HIV-infected and control subjects. J Acquir Immune Defic Syndr Hum Retrovirol 1999, 20:228-237.
40. Sutinen J., Hakkinen A.M., Westerbacka J., Seppala-Lindroos A., Vehkavaara S., Halavaara J., et al. Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy. AIDS 2002, 16:2183-2193.
41. Wohl D.A., McComsey G., Tebas P., et al. Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Clin Infect Dis 2006, 43:645-653.
42. Sutinen J., Kannisto K., Korsheninnikova E., Nyman T., Ehrenborg E., Andrew R., et al. In the lipodystrophy associated with highly active antiretroviral therapy, pseudo-Cushing's syndrome is associated with increased regeneration of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue. Diabetologia 2004, 47:1668-1671.
43. Currier J.S., Havlir D.V. Complications of HIV disease and antiretroviral therapy. Top HIV Med 2004, 12:31-45. Highlights of the 11th Conference on Retroviruses and Opportunistic Infections, February 8-11, 2004, San Francisco, California, USA.
44. Grunfeld C., Kotler D.P., Hamadeh R., Tierney A., Wang J., Pierson R.N. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1989, 86:27-31.
45. Friis-Moller N., Weber R., Reiss P., Thiebaut R., Kirk O., d'Arminio Monforte A., et al. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS 2003, 17:1179-1193.
46. Periard D., Telenti A., Sudre P., Cheseaux J.J., Halfon P., Reymond M.J., et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 1999, 100:700-705.
47. Liang J.S., Distler O., Cooper D.A., Jamil H., Deckelbaum R.J., Ginsberg H.N., et al. HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med 2001, 7:1327-1331.
48. Purnell J.Q., Zambon A., Knopp R.H., Pizzuti D.J., Achari R., Leonard J.M., et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 2000, 14:51-57.
49. Ranganathan S., Kern P.A. The HIV protease inhibitor saquinavir impairs lipid metabolism and glucose transport in cultured adipocytes. J Endocrinol 2002, 172:155-162.
50. Reeds D.N., Mittendorfer B., Patterson B.W., Powderly W.G., Yarasheski K.E., Klein S. Alterations in lipid kinetics in men with HIV-dyslipidemia. Am J Physiol Endocrinol Metab 2003, 285:E490-E497.
51. Dube M.P., Stein J.H., Aberg J.A., Fichtenbaum C.J., Gerber J.G., Tashima K.T., et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003, 37:613-627.
52. van Leth F., Phanuphak P., Ruxrungtham K., Baraldi E., Miller S., Gazzard B., et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004, 363:1253-1263.
53. Duong M., Petit J.M., Piroth L., Grappin M., Buisson M., Chavanet P., et al. Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy. J Acquir Immune Defic Syndr 2001, 27:245-250. 1999.
54. Brown T.T., Cole S.R., Li X., Kingsley L.A., Palella F.J., Riddler S.A., et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 2005, 165:1179-1184.
55. Samaras K., Wand H., Law M., Emery S., Cooper D., Carr A. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia. Diabetes Care 2007, 30:113-119.
56. Noor M.A., Lo J.C., Mulligan K., Schwarz J.M., Halvorsen R.A., Schambelan M., et al. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 2001, 15:F11-F18.
57. Noor M.A., Parker R.A., O'Mara E., Grasela D.M., Currie A., Hodder S.L., et al. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS 2004, 18:2137-2144.
58. Wanke C., Gerrior J., Hendricks K., McNamara J., Schaefer E. Alterations in lipid profiles in HIV-infected patients treated with protease inhibitor therapy are not influenced by diet. Nutr Clin Pract 2005, 20:668-673.
59. Serghides L., Nathoo S., Walmsley S., Kain K.C. CD36 deficiency induced by antiretroviral therapy. AIDS 2002, 16:353-358.
60. Lee G.A., Mafong D.D., Noor M.A., Lo J.C., Mulligan K., Schwarz J.M., et al. HIV protease inhibitors increase adiponectin levels in HIV-negative men. J Acquir Immune Defic Syndr 2004, 36:645-647. 1999.
61. Murata H., Hruz P.W., Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000, 275:20251-20254.
62. Beatty G., Khalili M., Abbasi F., Chu J., Reaven G.M., Rosen A., et al. Quantification of insulin-mediated glucose disposal in HIV-infected individuals: comparison of patients treated and untreated with protease inhibitors. J Acquir Immune Defic Syndr 2003, 33:34-40. 1999.
63. Meininger G., Hadigan C., Laposata M., Brown J., Rabe J., Louca J., et al. Elevated concentrations of free fatty acids are associated with increased insulin response to standard glucose challenge in human immunodeficiency virus-infected subjects with fat redistribution. Metabolism 2002, 51:260-266.
64. Andersen O., Haugaard S.B., Andersen U.B., Friis-Moller N., Storgaard H., Volund A., et al. Lipodystrophy in human immunodeficiency virus patients impairs insulin action and induces defects in beta-cell function. Metabolism 2003, 52:1343-1353.
65. Haugaard S.B., Andersen O., Storgaard H., Dela F., Holst J.J., Iversen J., et al. Insulin secretion in lipodystrophic HIV-infected patients is associated with high levels of nonglucose secretagogues and insulin resistance of beta-cells. Am J Physiol Endocrinol Metab 2004, 287:E677-E685.
66. Kino T., Gragerov A., Slobodskaya O., Tsopanomichalou M., Chrousos G.P., Pavlakis G.N. Human immunodeficiency virus type 1 (HIV-1) accessory protein Vpr induces transcription of the HIV-1 and glucocorticoid-responsive promoters by binding directly to p300/CBP coactivators. J Virol 2002, 76:9724-9734.
67. Shrivastav S, Kino T, Chrousos GP, Kopp JB. HIV-1 Vpr binds and inhibits PPAR-gamma: implications for HIV-associated insulin resistance and lipodystrophy. In: International Meeting of the Institute of Human Virology; Baltimore; 2000.
68. Kino T., De Martino M.U., Charmandari E., Ichijo T., Outas T., Chrousos G.P. HIV-1 accessory protein Vpr inhibits the effect of insulin on the Foxo subfamily of forkhead transcription factors by interfering with their binding to 14-3-3 proteins: potential clinical implications regarding the insulin resistance of HIV-1-infected patients. Diabetes 2005, 54:23-31.
69. Baumann H., Morella K.K., White D.W., Dembski M., Bailon P.S., Kim H., et al. The full-length leptin receptor has signaling capabilities of interleukin 6-type cytokine receptors. Proc Natl Acad Sci U S A 1996, 93:8374-8378.
70. Friedman J.M., Halaas J.L. Leptin and the regulation of body weight in mammals. Nature 1998, 395:763-770.
71. Hwa J.J., Ghibaudi L., Compton D., Fawzi A.B., Strader C.D. Intracerebroventricular injection of leptin increases thermogenesis and mobilizes fat metabolism in ob/ob mice. Horm Metab Res 1996, 28:659-663.
72. Chan J.L., Heist K., DePaoli A.M., Veldhuis J.D., Mantzoros C.S. The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men. J Clin Invest 2003, 111:1409-1421.
73. Yarasheski K.E., Zachwieja J.J., Horgan M.M., Powderly W.G., Santiago J.V., Landt M. Serum leptin concentrations in human immunodeficiency virus-infected men with low adiposity. Metabolism 1997, 46:303-305.
74. Grunfeld C., Pang M., Shigenaga J.K., Jensen P., Lallone R., Friedman J., et al. Serum leptin levels in the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1996, 81:4342-4346.
75. Schindler K., Haider D., Wolzt M., Rieger A., Gmeinhart B., Luger A., et al. Impact of antiretroviral therapy on visfatin and retinol-binding protein 4 in HIV-infected subjects. Eur J Clin Invest 2006, 36:640-646.
76. Nagy G.S., Tsiodras S., Martin L.D., Avihingsanon A., Gavrila A., Hsu W.C., et al. Human immunodeficiency virus type 1-related lipoatrophy and lipohypertrophy are associated with serum concentrations of leptin. Clin Infect Dis 2003, 36:795-802.
77. Vernochet C., Azoulay S., Duval D., Guedj R., Cottrez F., Vidal H., et al. Human immunodeficiency virus protease inhibitors accumulate into cultured human adipocytes and alter expression of adipocytokines. J Biol Chem 2005, 280:2238-2243.
78. Kosmiski L., Kuritzkes D., Lichtenstein K., Eckel R. Adipocyte-derived hormone levels in HIV lipodystrophy. Antivir Ther 2003, 8:9-15.
79. Vigouroux C., Maachi M., Nguyen T.H., Coussieu C., Gharakhanian S., Funahashi T., et al. Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy. AIDS 2003, 17:1503-1511.
80. Wunder D., Bersinger N.A., Fux C., Weber R., Bernasconi E., Cavassini M., et al. Plasma leptin levels in men are not related to the development of lipoatrophy during antiretroviral therapy. AIDS 2005, 19:1837-1842.
81. Kovacic J.C., Martin A., Carey D., Wand H., Mallon P.W., Feneley M.P., et al. Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy. Antivir Ther 2005, 10:135-143.
82. Rossetti L., Massillon D., Barzilai N., Vuguin P., Chen W., Hawkins M., et al. Short term effects of leptin on hepatic gluconeogenesis and in vivo insulin action. J Biol Chem 1997, 272:27758-27763.
83. Zhao Y.F., Feng D.D., Chen C. Contribution of adipocyte-derived factors to beta-cell dysfunction in diabetes. Int J Biochem Cell Biol 2006, 38:804-819.
84. Rouru J., Cusin I., Zakrzewska K.E., Jeanrenaud B., Rohner-Jeanrenaud F. Effects of intravenously infused leptin on insulin sensitivity and on the expression of uncoupling proteins in brown adipose tissue. Endocrinology 1999, 140:3688-3692.
85. Siegrist-Kaiser C.A., Pauli V., Juge-Aubry C.E., Boss O., Pernin A., Chin W.W., et al. Direct effects of leptin on brown and white adipose tissue. J Clin Invest 1997, 100:2858-2864.
86. Kamohara S., Burcelin R., Halaas J.L., Friedman J.M., Charron M.J. Acute stimulation of glucose metabolism in mice by leptin treatment. Nature 1997, 389:374-377.
87. Maeda K., Okubo K., Shimomura I., Funahashi T., Matsuzawa Y., Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996, 221:286-289.
88. Iwaki M., Matsuda M., Maeda N., Funahashi T., Matsuzawa Y., Makishima M., et al. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 2003, 52:1655-1663.
89. Maeda N., Takahashi M., Funahashi T., Kihara S., Nishizawa H., Kishida K., et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001, 50:2094-2099.
90. Weyer C., Funahashi T., Tanaka S., Hotta K., Matsuzawa Y., Pratley R.E., et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001, 86:1930-1935.
91. Stefan N., Vozarova B., Funahashi T., Matsuzawa Y., Weyer C., Lindsay R.S., et al. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 2002, 51:1884-1888.
92. Haque W.A., Shimomura I., Matsuzawa Y., Garg A. Serum adiponectin and leptin levels in patients with lipodystrophies. J Clin Endocrinol Metab 2002, 87:2395.
93. Yamauchi T., Kamon J., Minokoshi Y., Ito Y., Waki H., Uchida S., et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002, 8:1288-1295.
94. Yamauchi T., Kamon J., Ito Y., Tsuchida A., Yokomizo T., Kita S., et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003, 423:762-769.
95. Neumeier M., Sigruener A., Eggenhofer E., Weigert J., Weiss T.S., Schaeffler A., et al. High molecular weight adiponectin reduces apolipoprotein B and E release in human hepatocytes. Biochem Biophys Res Commun 2007, 352:543-548.
96. Xu S.Q., Mahadev K., Wu X., Fuchsel L., Donnelly S., Scalia R.G., et al. Adiponectin protects against angiotensin II or tumor necrosis factor alpha-induced endothelial cell monolayer hyperpermeability: role of cAMP/PKA signaling. Arterioscler Thromb Vasc Biol 2008, 28:899-905.
97. Touyz R.M. Endothelial cell IL-8, a new target for adiponectin: implications in vascular protection. Circ Res 2005, 97:1216-1219.
98. Mossalam M., Jeong J.H., Abel E.D., Kim S.W., Kim Y.H. Reversal of oxidative stress in endothelial cells by controlled release of adiponectin. J Control Release 2008, 130:234-237.
99. Kato H., Kashiwagi H., Shiraga M., Tadokoro S., Kamae T., Ujiie H., et al. Adiponectin acts as an endogenous antithrombotic factor. Arterioscler Thromb Vasc Biol 2006, 26:224-230.
100. Plant S., Shand B., Elder P., Scott R. Adiponectin attenuates endothelial dysfunction induced by oxidised low-density lipoproteins. Diab Vasc Dis Res 2008, 5:102-108.
101. Dolan S.E., Hadigan C., Killilea K.M., Sullivan M.P., Hemphill L., Lees R.S., et al. Increased cardiovascular disease risk indices in HIV-infected women. J Acquir Immune Defic Syndr 2005, 39:44-54. 1999.
102. Das S., Shahmanesh M., Stolinski M., Shojaee-Moradie F., Jefferson W., Jackson N.C., et al. In treatment-naive and antiretroviral-treated subjects with HIV, reduced plasma adiponectin is associated with a reduced fractional clearance rate of VLDL, IDL and LDL apolipoprotein B-100. Diabetologia 2006, 49:538-542.
103. Addy C.L., Gavrila A., Tsiodras S., Brodovicz K., Karchmer A.W., Mantzoros C.S. Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. J Clin Endocrinol Metab 2003, 88:627-636.
104. Chaparro J., Reeds D.N., Wen W., Xueping E., Klein S., Semenkovich C.F., et al. Alterations in thigh subcutaneous adipose tissue gene expression in protease inhibitor-based highly active antiretroviral therapy. Metabolism 2005, 54:561-567.
105. Jones S.P., Janneh O., Back D.J., Pirmohamed M. Altered adipokine response in murine 3T3-F442A adipocytes treated with protease inhibitors and nucleoside reverse transcriptase inhibitors. Antivir Ther 2005, 10:207-213.
106. van Wijk J.P., de Koning E.J., Cabezas M.C., op't Roodt J., Joven J., Rabelink T.J., et al. Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial. Ann Intern Med 2005, 143:337-346.
107. Grigem S., Fischer-Posovszky P., Debatin K.M., Loizon E., Vidal H., Wabitsch M. The effect of the HIV protease inhibitor ritonavir on proliferation, differentiation, lipogenesis, gene expression and apoptosis of human preadipocytes and adipocytes. Horm Metab Res 2005, 37:602-609.
108. Lagathu C., Bastard J.P., Auclair M., Maachi M., Kornprobst M., Capeau J., et al. Antiretroviral drugs with adverse effects on adipocyte lipid metabolism and survival alter the expression and secretion of proinflammatory cytokines and adiponectin in vitro. Antivir Ther 2004, 9:911-920.
109. Sankale J.L., Tong Q., Hadigan C.M., Tan G., Grinspoon S.K., Kanki P.J., et al. Regulation of adiponectin in adipocytes upon exposure to HIV-1. HIV Med 2006, 7:268-274.
110. Verkauskiene R., Dollfus C., Levine M., Faye A., Deghmoun S., Houang M., et al. Serum adiponectin and leptin concentrations in HIV-infected children with fat redistribution syndrome. Pediatr Res 2006, 60:225-230.
111. Kim R.J., Carlow D.C., Rutstein J.H., Rutstein R.M. Hypoadiponectinemia, dyslipidemia, and impaired growth in children with HIV-associated facial lipoatrophy. J Pediatr Endocrinol Metab 2007, 20:65-74.
112. Leitner J.M., Pernerstorfer-Schoen H., Weiss A., Schindler K., Rieger A., Jilma B. Age and sex modulate metabolic and cardiovascular risk markers of patients after 1 year of highly active antiretroviral therapy (HAART). Atherosclerosis 2006, 187:177-185.
113. Marso S.P., Mehta S.K., Frutkin A., House J.A., McCrary J.R., Kulkarni K.R. Low adiponectin levels are associated with atherogenic dyslipidemia and lipid-rich plaque in nondiabetic coronary arteries. Diabetes Care 2008, 31:989-994.
114. Shankar A., Marshall S., Li J. The association between plasma adiponectin level and hypertension. Acta Cardiol 2008, 63:160-165.
115. Steppan C.M., Bailey S.T., Bhat S., Brown E.J., Banerjee R.R., Wright C.M., et al. The hormone resistin links obesity to diabetes. Nature 2001, 409:307-312.
116. Morash B.A., Willkinson D., Ur E., Wilkinson M. Resistin expression and regulation in mouse pituitary. FEBS Lett 2002, 526:26-30.
117. Nogueiras R., Gallego R., Gualillo O., Caminos J.E., Garcia-Caballero T., Casanueva F.F., et al. Resistin is expressed in different rat tissues and is regulated in a tissue- and gender-specific manner. FEBS Lett 2003, 548:21-27.
118. Chen C.C., Li T.C., Li C.I., Liu C.S., Wang H.J., Lin C.C. Serum resistin level among healthy subjects: relationship to anthropometric and metabolic parameters. Metabolism 2005, 54:471-475.
119. Lee J.H., Chan J.L., Yiannakouris N., Kontogianni M., Estrada E., Seip R., et al. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab 2003, 88:4848-4856.
120. Silha J.V., Krsek M., Skrha J.V., Sucharda P., Nyomba B.L., Murphy L.J. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. Eur J Endocrinol 2003, 149:331-335.
121. Utzschneider K.M., Carr D.B., Tong J., Wallace T.M., Hull R.L., Zraika S., et al. Resistin is not associated with insulin sensitivity or the metabolic syndrome in humans. Diabetologia 2005, 48:2330-2333.
122. Ghosh S., Singh A.K., Aruna B., Mukhopadhyay S., Ehtesham N.Z. The genomic organization of mouse resistin reveals major differences from the human resistin: functional implications. Gene 2003, 305:27-34.
123. Barb D., Wadhwa S.G., Kratzsch J., Gavrila A., Chan J.L., Williams C.J., et al. Circulating resistin levels are not associated with fat redistribution, insulin resistance, or metabolic profile in patients with the highly active antiretroviral therapy-induced metabolic syndrome. J Clin Endocrinol Metab 2005, 90:5324-5328.
124. Ranade K., Geese W.J., Noor M., Flint O., Tebas P., Mulligan K., et al. Genetic analysis implicates resistin in HIV lipodystrophy. AIDS 2008, 22:1561-1568.
125. Kamin D., Hadigan C., Lehrke M., Mazza S., Lazar M.A., Grinspoon S. Resistin levels in human immunodeficiency virus-infected patients with lipoatrophy decrease in response to rosiglitazone. J Clin Endocrinol Metab 2005, 90:3423-3426.
126. Yang Q., Graham T.E., Mody N., Preitner F., Peroni O.D., Zabolotny J.M., et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005, 436:356-362.
127. Herman M.A., Kahn B.B. Glucose transport and sensing in the maintenance of glucose homeostasis and metabolic harmony. J Clin Invest 2006, 116:1767-1775.
128. Haider D.G., Schindler K., Mittermayer F., Muller M., Nowotny P., Rieger A., et al. Effect of rosiglitazone on visfatin and retinol-binding protein-4 plasma concentrations in HIV-positive patients. Clin Pharmacol Ther 2007, 81:580-585.
129. Adeghate E. Visfatin: structure, function and relation to diabetes mellitus and other dysfunctions. Curr Med Chem 2008, 15:1851-1862.
130. Samal B., Sun Y., Stearns G., Xie C., Suggs S., McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 1994, 14:1431-1437.
131. Curat C.A., Wegner V., Sengenes C., Miranville A., Tonus C., Busse R., et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006, 49:744-747.
132. Berndt J., Kloting N., Kralisch S., Kovacs P., Fasshauer M., Schon M.R., et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005, 54:2911-2916.
133. Haider D.G., Schindler K., Schaller G., Prager G., Wolzt M., Ludvik B. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 2006, 91:1578-1581.
134. Jia S.H., Li Y., Parodo J., Kapus A., Fan L., Rotstein O.D., et al. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 2004, 113:1318-1327.
135. Ognjanovic S., Bryant-Greenwood G.D. Pre-B-cell colony-enhancing factor, a novel cytokine of human fetal membranes. Am J Obstet Gynecol 2002, 187:1051-1058.
136. Garcia J.G. Searching for candidate genes in acute lung injury: SNPs, Chips and PBEF. Trans Am Clin Climatol Assoc 2005, 116:205-219. discussion 20.
137. Ye S.Q., Simon B.A., Maloney J.P., Zambelli-Weiner A., Gao L., Grant A., et al. Pre-B-cell colony-enhancing factor as a potential novel biomarker in acute lung injury. Am J Respir Crit Care Med 2005, 171:361-370.
138. Chen M.P., Chung F.M., Chang D.M., Tsai J.C., Huang H.F., Shin S.J., et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006, 91:295-299.
139. Kloting N., Berndt J., Kralisch S., Kovacs P., Fasshauer M., Schon M.R., et al. Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem Biophys Res Commun 2006, 339:430-436.
140. Pagano C., Pilon C., Olivieri M., Mason P., Fabris R., Serra R., et al. Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 2006, 91:3165-3170.
141. Lee D.K., Cheng R., Nguyen T., Fan T., Kariyawasam A.P., Liu Y., et al. Characterization of apelin, the ligand for the APJ receptor. J Neurochem 2000, 74:34-41.
142. Habata Y., Fujii R., Hosoya M., Fukusumi S., Kawamata Y., Hinuma S., et al. Apelin, the natural ligand of the orphan receptor APJ, is abundantly secreted in the colostrum. Biochim Biophys Acta 1999, 1452:25-35.
143. Medhurst A.D., Jennings C.A., Robbins M.J., Davis R.P., Ellis C., Winborn K.Y., et al. Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin. J Neurochem 2003, 84:1162-1172.
144. Boucher J., Masri B., Daviaud D., Gesta S., Guigne C., Mazzucotelli A., et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology 2005, 146:1764-1771.
145. Heinonen M.V., Purhonen A.K., Miettinen P., Paakkonen M., Pirinen E., Alhava E., et al. Apelin, orexin-A and leptin plasma levels in morbid obesity and effect of gastric banding. Regul Pept 2005, 130:7-13.
146. Chen M.M., Ashley E.A., Deng D.X., Tsalenko A., Deng A., Tabibiazar R., et al. Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction. Circulation 2003, 108:1432-1439.
147. Foldes G., Horkay F., Szokodi I., Vuolteenaho O., Ilves M., Lindstedt K.A., et al. Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure. Biochem Biophys Res Commun 2003, 308:480-485.
148. Puffer B.A., Sharron M., Coughlan C.M., Baribaud F., McManus C.M., Lee B., et al. Expression and coreceptor function of APJ for primate immunodeficiency viruses. Virology 2000, 276:435-444.
149. Zou M.X., Liu H.Y., Haraguchi Y., Soda Y., Tatemoto K., Hoshino H. Apelin peptides block the entry of human immunodeficiency virus (HIV). FEBS Lett 2000, 473:15-18.
150. Wei L., Hou X., Tatemoto K. Regulation of apelin mRNA expression by insulin and glucocorticoids in mouse 3T3-L1 adipocytes. Regul Pept 2005, 132:27-32.
151. Esposito V., De Falco M., De Luca L., Acanfora F., Onori N., Loiacono L., et al. Immunohistochemical study of apelin, the natural ligand of receptor APJ, in a case of AIDS-related cachexia. In Vivo 2002, 16:337-340.
152. Maslowska M., Wang H.W., Cianflone K. Novel roles for acylation stimulating protein/C3adesArg: a review of recent in vitro and in vivo evidence. Vitam Horm 2005, 70:309-332.
153. Cianflone K., Xia Z., Chen L.Y. Critical review of acylation-stimulating protein physiology in humans and rodents. Biochim Biophys Acta 2003, 1609:127-143.
154. Kotler D.P., Ionescu G., Johnson J.A., Inada Y., He Q., Engelson E.S., et al. Studies of adipose tissue metabolism in human immunodeficiency virus-associated lipodystrophy. Clin Infect Dis 2003, 37(Suppl. 2):S47-S51.
155. Cianflone K., Zakarian R., Stanculescu C., Germinario R. Protease inhibitor effects on triglyceride synthesis and adipokine secretion in human omental and subcutaneous adipose tissue. Antivir Ther 2006, 11:681-691.
156. Rabe K., Lehrke M., Parhofer K.G., Broedl U.C. Adipokines and insulin resistance. Mol Med 2008, 14:741-751.
157. de Souza Batista C.M., Yang R.Z., Lee M.J., Glynn N.M., Yu D.Z., Pray J., et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007, 56:1655-1661.
158. Schaffler A., Zeitoun M., Wobser H., Buechler C., Aslanidis C., Herfarth H. Frequency and significance of the novel single nucleotide missense polymorphism Val109Asp in the human gene encoding omentin in Caucasian patients with type 2 diabetes mellitus or chronic inflammatory bowel diseases. Cardiovasc Diabetol 2007, 6:3.
159. Tan B.K., Adya R., Farhatullah S., Lewandowski K.C., O'Hare P., Lehnert H., et al. Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes 2008, 57:801-808.
160. Tan B.K., Pua S., Syed F., Lewandowski K.C., O'Hare J.P., Randeva H.S. Decreased plasma omentin-1 levels in Type 1 diabetes mellitus. Diabet Med 2008, 25:1254-1255.
161. Hida K., Wada J., Eguchi J., Zhang H., Baba M., Seida A., et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci U S A 2005, 102:10610-10615.
162. Fain J.N., Buehrer B., Bahouth S.W., Tichansky D.S., Madan A.K. Comparison of messenger RNA distribution for 60 proteins in fat cells vs the nonfat cells of human omental adipose tissue. Metabolism 2008, 57:1005-1015.
163. Youn B.S., Kloting N., Kratzsch J., Lee N., Park J.W., Song E.S., et al. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes 2008, 57:372-377.
164. Lago F., Dieguez C., Gomez-Reino J., Gualillo O. The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine Growth Factor Rev 2007, 18:313-325.
165. Chan J.L., Matarese G., Shetty G.K., Raciti P., Kelesidis I., Aufiero D., et al. Differential regulation of metabolic, neuroendocrine, and immune function by leptin in humans. Proc Natl Acad Sci U S A 2006, 103:8481-8486.
166. Kelesidis T., Mantzoros C.S. The emerging role of leptin in humans. Pediatr Endocrinol Rev 2006, 3:239-248.
167. Matarese G., Moschos S., Mantzoros C.S. Leptin in immunology. J Immunol 2005, 174:3137-3142.
168. Raso G.M., Pacilio M., Esposito E., Coppola A., Di Carlo R., Meli R. Leptin potentiates IFN-gamma-induced expression of nitric oxide synthase and cyclo-oxygenase-2 in murine macrophage J774A.1. Br J Pharmacol 2002, 137:799-804.
169. Loffreda S., Yang S.Q., Lin H.Z., Karp C.L., Brengman M.L., Wang D.J., et al. Leptin regulates proinflammatory immune responses. Faseb J 1998, 12:57-65.
170. Caldefie-Chezet F., Poulin A., Vasson M.P. Leptin regulates functional capacities of polymorphonuclear neutrophils. Free Radic Res 2003, 37:809-814.
171. Caldefie-Chezet F., Poulin A., Tridon A., Sion B., Vasson M.P. Leptin: a potential regulator of polymorphonuclear neutrophil bactericidal action?. J Leukoc Biol 2001, 69:414-418.
172. Bruno A., Conus S., Schmid I., Simon H.U. Apoptotic pathways are inhibited by leptin receptor activation in neutrophils. J Immunol 2005, 174:8090-8096.
173. Conus S., Bruno A., Simon H.U. Leptin is an eosinophil survival factor. J Allergy Clin Immunol 2005, 116:1228-1234.
174. Martin-Romero C., Santos-Alvarez J., Goberna R., Sanchez-Margalet V. Human leptin enhances activation and proliferation of human circulating T lymphocytes. Cell Immunol 2000, 199:15-24.
175. Papathanassoglou E., El-Haschimi K., Li X.C., Matarese G., Strom T., Mantzoros C. Leptin receptor expression and signaling in lymphocytes: kinetics during lymphocyte activation, role in lymphocyte survival, and response to high fat diet in mice. J Immunol 2006, 176:7745-7752.
176. Mattioli B., Straface E., Quaranta M.G., Giordani L., Viora M. Leptin promotes differentiation and survival of human dendritic cells and licenses them for Th1 priming. J Immunol 2005, 174:6820-6828.
177. Busso N., So A., Chobaz-Peclat V., Morard C., Martinez-Soria E., Talabot-Ayer D., et al. Leptin signaling deficiency impairs humoral and cellular immune responses and attenuates experimental arthritis. J Immunol 2002, 168:875-882.
178. Ozata M., Ozdemir I.C., Licinio J. Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects. J Clin Endocrinol Metab 1999, 84:3686-3695.
179. Ouchi N., Kihara S., Arita Y., Nishida M., Matsuyama A., Okamoto Y., et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001, 103:1057-1063.
180. Fernandez-Real J.M., Lopez-Bermejo A., Casamitjana R., Ricart W. Novel interactions of adiponectin with the endocrine system and inflammatory parameters. J Clin Endocrinol Metab 2003, 88:2714-2718.
181. Yamaguchi N., Argueta J.G., Masuhiro Y., Kagishita M., Nonaka K., Saito T., et al. Adiponectin inhibits toll-like receptor family-induced signaling. FEBS Lett 2005, 579:6821-6826.
182. Tsatsanis C., Zacharioudaki V., Androulidaki A., Dermitzaki E., Charalampopoulos I., Minas V., et al. Adiponectin induces TNF-alpha and IL-6 in macrophages and promotes tolerance to itself and other pro-inflammatory stimuli. Biochem Biophys Res Commun 2005, 335:1254-1263.
183. Wulster-Radcliffe M.C., Ajuwon K.M., Wang J., Christian J.A., Spurlock M.E. Adiponectin differentially regulates cytokines in porcine macrophages. Biochem Biophys Res Commun 2004, 316:924-929.
184. Rothenbacher D., Brenner H., Marz W., Koenig W. Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers. Eur Heart J 2005, 26:1640-1646.
185. Mantzoros C.S. Whither recombinant human leptin treatment for HIV-associated lipoatrophy and the metabolic syndrome?. J Clin Endocrinol Metab 2009, 94:1089-1091.
186. Riddle T.M., Fichtenbaum C.J., Hui D.Y. Leptin replacement therapy but not dietary polyunsaturated fatty acid alleviates HIV protease inhibitor-induced dyslipidemia and lipodystrophy in mice. J Acquir Immune Defic Syndr 2003, 33:564-570. 1999.
187. Xu A., Yin S., Wong L., Chan K.W., Lam K.S. Adiponectin ameliorates dyslipidemia induced by the human immunodeficiency virus protease inhibitor ritonavir in mice. Endocrinology 2004, 145:487-494.
188. Lee J.H., Chan J.L., Sourlas E., Raptopoulos V., Mantzoros C.S. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy. J Clin Endocrinol Metab 2006, 91:2605-2611.
189. Mulligan K., Khatami H., Schwarz J.M., Sakkas G.K., Depaoli A.M., Tai V.W., et al. The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with HIV-associated lipoatrophy and hypoleptinemia. J Clin Endocrinol Metab 2009.
190. Brennan A.M., Lee J.H., Tsiodras S., Chan J.L., Doweiko J., Chimienti S.N., et al. r-metHuLeptin improves highly active antiretroviral therapy-induced lipoatrophy and the metabolic syndrome, but not through altering circulating IGF and IGF-binding protein levels: observational and interventional studies in humans. Eur J Endocrinol 2009, 160:173-176.
191. Carr A., Workman C., Carey D., Rogers G., Martin A., Baker D., et al. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet 2004, 363:429-438.
192. Gavrila A., Hsu W., Tsiodras S., Doweiko J., Gautam S., Martin L., et al. Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 × 2 factorial, randomized, double-blinded, placebo-controlled trial. Clin Infect Dis 2005, 40:745-749.
193. Gelato M.C., Mynarcik D.C., Quick J.L., Steigbigel R.T., Fuhrer J., Brathwaite C.E., et al. Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study. J Acquir Immune Defic Syndr 2002, 31:163-170. 1999.
194. Hadigan C., Yawetz S., Thomas A., Havers F., Sax P.E., Grinspoon S. Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Ann Intern Med 2004, 140:786-794.
195. Sutinen J., Hakkinen A.M., Westerbacka J., Seppala-Lindroos A., Vehkavaara S., Halavaara J., et al. Rosiglitazone in the treatment of HAART-associated lipodystrophy-a randomized double-blind placebo-controlled study. Antivir Ther 2003, 8:199-207.
196. Tomazic J., Karner P., Vidmar L., Maticic M., Sharma P.M., Janez A. Effect of metformin and rosiglitazone on lipid metabolism in HIV infected patients receiving protease inhibitor containing HAART. Acta Dermatovenerol Alp Panonica Adriat 2005, 14:99-105.
197. Mulligan K., Yang Y., Wininger D.A., Koletar S.L., Parker R.A., Alston-Smith B.L., et al. Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio. AIDS 2007, 21:47-57.
198. Sutinen J. The Effects of thiazolidinediones on metabolic complications and lipodystrophy in HIV-infected patients. PPAR Res 2009, 2009:373524.
199. Feldt T., Oette M., Kroidl A., Goebels K., Fritzen R., Kambergs J., et al. Evaluation of safety and efficacy of rosiglitazone in the treatment of HIV-associated lipodystrophy syndrome. Infection 2006, 34:55-61.
200. Giralt M., Domingo P., Guallar J.P., Rodriguez de la Concepcion M.L., Alegre M., Domingo J.C., et al. HIV-1 infection alters gene expression in adipose tissue, which contributes to HIV-1/HAART-associated lipodystrophy. Antivir Ther 2006, 11:729-740.